Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type 2 diabetes mellitus: a case report

Journal of Medical Case Reports

Yousef Shukha¹  Riad Taher²  Brian Vadasz³  Mattan Arazi³  Ofir Koren⁴ 

[1] Internal Medicine Department E, Rambam HealthCare Campus, POD 4147, Ein IbrahimUmm alfahm, 300100, Haifa, Israel;Internal Medicine Department E, Rambam HealthCare Campus, POD 4147, Ein IbrahimUmm alfahm, 300100, Haifa, Israel;Department of Endocrinology, Rambam HealthCare Campus, Haifa, Israel;The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel;The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel;Heart Institute, Emek Medical Center, Afula, Israel;

关键词: Diabetic ketoacidosis;    Sodium-glucose cotransporter 2 inhibitors (SGLT2i);    Latent autoimmune diabetes in adults (LADA);   

DOI  :  10.1186/s13256-020-02607-2

来源: Springer

【 摘 要 】

BackgroundEuglycemic diabetic ketoacidosis is an uncommon but life-threatening complication associated with the use of sodium-glucose cotransporter 2 inhibitors that causes lower than expected blood glucose levels typically seen in diabetic ketoacidosis.Case presentationWe present a case of 64-year-old Caucasian male patient previously diagnosed with type 2 diabetes treated with a sodium-glucose cotransporter 2 inhibitor who developed severe ketoacidosis. Serum glucose levels on initial presentation were slightly above normal baseline level. The patient was revealed to have latent autoimmune diabetes in adults.ConclusionThis case highlights the importance of prescribing sodium-glucose cotransporter 2 inhibitors to the correct patient population and the significance of accurately differentiating between various types of diabetes.

【 授权许可】

CC BY